Many physicians turn to the FDA-approved drug label (package insert) for information about genetic testing that can be used to optimize drug response, also known as pharmacogenomics/pharmacogenetics (PGx). Information about PGx appears in the labels of hundreds of drugs, but how reliable and useful is this information?
The genetic testing landscape has changed dramatically in the past decades and continues to evolve as different delivery models and markets are being explored. In this post, we’ll discuss how the genetic testing industry has developed and some of the recent industry trends and factors impacting its growth.
The genetic basis of common diseases like diabetes, cancer, heart disease, asthma and Alzheimer’s disease is complex. The genetic underpinning of most cases of common diseases is not monogenic, but rather, polygenic. In other words, there are genetic variants of dozens of different genes, each with a tiny effect on disease risk.